Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
[3] [4] Clinical trials have demonstrated substantial reductions in hemoglobin A1c (up to 2.5% reduction from baseline) and body weight (up to 20% reduction from baseline) in the SURPASS and SURMOUNT clinical trial programs
A higher genetic barrier to resistance to HCV-796 and related compounds is therefore expected in patients infected with HCV subtype 1a than 1b
This information will be critical for patients, clinicians and policymakers to make informed decisions on the use of this important class of medications. 2
R.ZabalgogeazcoaI.et al
US$ 25.17
US$ 27.92
US$ 21.21
US$ 22.58
US$ 22.62
